Archives of Gynecology and Obstetrics

, Volume 298, Issue 5, pp 859–860 | Cite as

Is there a role for HIPEC in ovarian cancer?

  • Philipp HarterEmail author
  • Andreas du Bois
  • Jalid Sehouli
  • Sven Mahner
  • Ignace Vergote
  • Luis Chiva
  • Antonio Gonzalez-Martin
  • Christina Fotopoulou
News and Views


Hyperthermic intraperitoneal chemotherapy (HIPEC) is promoted by some as a standard treatment for peritoneal carcinomatosis of epithelial ovarian cancer (EOC) and other tumor entities, despite lack of robust data supporting this. Publicly available evidence addressing the value of HIPEC in EOC is rather inconclusive, revealing contradictory and inconsistent results while some studies even report harm to the patients from a higher morbidity. On this ground, we cannot recommend the implementation and use of HIPEC outside of a randomized clinical trial setting.


HIPEC Ovarian cancer Cytoreductive surgery Randomized trials 


Author contributions

Protocol/project development: Harter, Fotopoulou. Data collection or management: all authors. Data analysis: all authors. Manuscript writing/editing: all authors.


Not applicable.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.


  1. 1.
    Verwaal VJ, van Ruth S, de Bree E et al (2003) Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 21(20):3737–3743CrossRefPubMedCentralGoogle Scholar
  2. 2.
    Harter P, Mahner S, Hilpert F et al (2013) Statement by the Kommission OVAR of the AGO Study Group on the Use of HIPEC (Hyperthermic Intraperitoneal Chemotherapy) to Treat Primary and Recurrent Ovarian Cancer. Geburtshilfe Frauenheilkd 73(3):221–223CrossRefPubMedCentralGoogle Scholar
  3. 3.
    Harter P, du Bois A, Mahner S et al (2016) Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria and AGO Switzerland Regarding the Use of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer. Geburtshilfe Frauenheilkd 76(2):147–149CrossRefPubMedCentralGoogle Scholar
  4. 4.
    Quenet F, Elias D, Roca L. A Unicancer phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7. J Clin Oncol. 36;2018 (suppl; abstr LBA3503)Google Scholar
  5. 5.
    Spiliotis J, Halkia E, Lianos E et al (2015) Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol 22(5):1570–1575CrossRefPubMedCentralGoogle Scholar
  6. 6.
    Harter P, Reuss A, Sehouli J, Chiva L, du Bois A. Brief report about the role of hyperthermic intraperitoneal chemotherapy in a prospective randomized phase 3 study in recurrent ovarian cancer from Spiliotis et alGoogle Scholar
  7. 7.
    Van Driel W, Sikorska K, Schagen van Leeuwen J, et al. A phase 3 trial of hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer. J Clin Oncol. 35;2017 (suppl; abstr 5519)Google Scholar
  8. 8.
    Lim MC, Chang S-J, Yoo HJ, et al. Randomized trial of hyperthermic intraperitoneal chemotherapy (HIPEC) in women with primary advanced peritoneal, ovarian, and tubal cancer. J Clin Oncol. 35;2017 (suppl; abstr 5520)Google Scholar
  9. 9.
    van Driel WJ, Koole SN, Sikorska K et al (2018) Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med 378:230–240CrossRefPubMedCentralGoogle Scholar
  10. 10.
    Spriggs DR, Zivanovic O (2018) Ovarian cancer treatment—are we getting warmer? N Engl J Med. 378(3):293–294CrossRefPubMedCentralGoogle Scholar
  11. 11.
    Vergote I, Chiva L, du Bois A (2018) Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 378(14):1362–1363CrossRefPubMedCentralGoogle Scholar
  12. 12.
    Fotopoulou C, Sehouli J, Mahner S et al (2018) HIPEC: HOPE or HYPE in the fight against advanced ovarian cancer? Ann Oncol. CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of GynecologyKliniken Essen Mitte, Essen and Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study GroupEssenGermany
  2. 2.Department of GynecologyCharité Medical University of Berlin, Germany and North-Eastern German Society of Gynaecologic Oncology (NOGGO) Ovarian Cancer Study Group and AGO Study GroupBerlinGermany
  3. 3.Department of Obstetrics and GynecologyUniversity Hospital, Ludwig-Maximilians-University Munich and AGO Study GroupMunichGermany
  4. 4.University Hospitals Leuven and BGOGLeuvenBelgium
  5. 5.Department of Obstetrics and GynecologyClínica Universidad de Navarra and GEICO Study GroupMadridSpain
  6. 6.Department of Medical OncologyClínica Universidad de Navarra and GEICO Study GroupMadridSpain
  7. 7.Department of Surgery and Cancer, Gynecologic OncologyHammersmith Hospital, Imperial CollegeLondonUK

Personalised recommendations